center-forecasting-drug-response 
Pharmaceutical Technology
MAY 30, 2023
In an investor call on 19 May, Catalent reduced its annual net revenue forecast by approximately 10% compared to its February predictions. Catalent has enough drug stock to meet immediate customer demand, he added. Source: GlobalData Pharmaceutical Intelligence Center (Accessed 24 May 2023). ©GlobalData.
IDStewardship
NOVEMBER 26, 2023
In this article 3 clinical pharmacists provide insights, pulling from their advanced experience with beta-lactam therapeutic drug monitoring (TDM). Historically, therapeutic drug monitoring (TDM) has been widely utilized for vancomycin and aminoglycosides given the narrow therapeutic index.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 10, 2022
In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Now, amid a wave of innovation, investors and drugmakers are putting their weight behind the drug class. As such, companies are rethinking the existing landscape of drug development.
ISPE
MARCH 28, 2023
The pharmaceutical supply chain runs through the entire process of new drugs from innovation to clinical to approval. The capacity of the global supply chain determines whether drug R&D, production, and clinical trials can be carried out smoothly, and determines the speed of new drugs from R&D to market.
ISPE
MARCH 28, 2023
The pharmaceutical supply chain runs through the entire process of new drugs from innovation to clinical to approval. The capacity of the global supply chain determines whether drug R&D, production, and clinical trials can be carried out smoothly, and determines the speed of new drugs from R&D to market.
European Pharmaceutical Review
FEBRUARY 14, 2023
A key benefit of mRNA therapeutics is that manufacturing time is fast compared to antibodies or protein-based drugs. The research also identified other challenges for mRNA therapeutics’ delivery , including their high cost, susceptibility to degradation by ribonucleases and limitations with drug delivery systems.
Pharmaceutical Technology
FEBRUARY 13, 2023
According to the GlobalData Pharma Intelligence Center, there are currently 71 PROTACs in development in the oncology pipeline by non-academic developers, mostly clustering in the preclinical and discovery phases, with only 14 agents in clinical stages. Among 44 patients with measurable disease, two had confirmed partial responses.
Expert insights. Personalized for you.
52 
Let's personalize your content